MedImmune Inc., Micromet AG deal

Under a co-development deal, Micromet granted MEDI North American development rights to its MT103 bispecific T cell engager (BiTE) to treat non-Hodgkin's

Read the full 221 word article

How to gain access

Continue reading with a
two-week free trial.